Mark A. Varney
Fundador en Neurolixis, Inc. .
Cargos activos de Mark A. Varney
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Director/Miembro de la Junta | - | - |
Fundador | - | - |
Historial de carrera de Mark A. Varney
Antiguos cargos conocidos de Mark A. Varney.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
RESPIRERX PHARMACEUTICALS INC. | Director/Miembro de la Junta | 30/01/2006 | 22/03/2013 |
Contacto de Relaciones con Inversores | 16/06/2011 | 22/03/2013 | |
Public Communications Contact | 29/07/2010 | 22/03/2013 | |
Presidente | 30/01/2006 | 22/03/2013 | |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 01/06/2004 | 01/01/2006 |
BIONOMICS LIMITED | Corporate Officer/Principal | 01/06/2004 | 01/06/2004 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/09/1999 | 01/04/2003 |
Sibia Neurosciences, Inc. | Corporate Officer/Principal | 01/10/1994 | 01/09/1999 |
Formación de Mark A. Varney.
University of Oxford | Doctorate Degree |
University of Surrey | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Reino Unido | 3 |
Australia | 2 |
Operativa
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Investor Relations Contact | 1 |
Sectorial
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
RESPIRERX PHARMACEUTICALS INC. | Health Technology |
BIONOMICS LIMITED | Health Technology |
Empresas privadas | 3 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Sibia Neurosciences, Inc. | Health Technology |
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Commercial Services |
- Bolsa de valores
- Insiders
- Mark A. Varney
- Experiencia